[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI3542819T1 - Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide - Google Patents

Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide

Info

Publication number
SI3542819T1
SI3542819T1 SI201431889T SI201431889T SI3542819T1 SI 3542819 T1 SI3542819 T1 SI 3542819T1 SI 201431889 T SI201431889 T SI 201431889T SI 201431889 T SI201431889 T SI 201431889T SI 3542819 T1 SI3542819 T1 SI 3542819T1
Authority
SI
Slovenia
Prior art keywords
vaccine compositions
immunostimulatory oligonucleotides
novel vaccine
novel
immunostimulatory
Prior art date
Application number
SI201431889T
Other languages
English (en)
Inventor
Paul Joseph Dominowski
Sharath K. Rai
Laurel Mary Sly
Corey Patrick Cook
Duncan Mwangi
Dennis L. Foss
Richard Lee Krebs
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of SI3542819T1 publication Critical patent/SI3542819T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/002Protozoa antigens
    • A61K39/008Leishmania antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27Equine rhinopneumonitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16711Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201431889T 2013-05-14 2014-05-12 Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide SI3542819T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361823189P 2013-05-14 2013-05-14
EP19173426.8A EP3542819B1 (en) 2013-05-14 2014-05-12 Novel vaccine compositions comprising immunostimulatory oligonucleotides

Publications (1)

Publication Number Publication Date
SI3542819T1 true SI3542819T1 (sl) 2021-11-30

Family

ID=50897961

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431889T SI3542819T1 (sl) 2013-05-14 2014-05-12 Sestave novih cepiv, ki vsebujejo imunostimulatorne oligonukleotide

Country Status (21)

Country Link
EP (2) EP2996719B1 (sl)
JP (2) JP6505084B2 (sl)
CN (2) CN108079290A (sl)
AR (1) AR096277A1 (sl)
AU (2) AU2014265649B2 (sl)
BR (1) BR112015028748A2 (sl)
CA (2) CA3027289A1 (sl)
DK (1) DK3542819T3 (sl)
ES (2) ES2894138T3 (sl)
HK (1) HK1219426A1 (sl)
HR (1) HRP20211452T1 (sl)
HU (1) HUE056040T2 (sl)
LT (1) LT3542819T (sl)
MX (2) MX367268B (sl)
PL (1) PL3542819T3 (sl)
PT (2) PT3542819T (sl)
RU (1) RU2627447C2 (sl)
SI (1) SI3542819T1 (sl)
SM (1) SMT202100602T1 (sl)
WO (1) WO2014186291A1 (sl)
ZA (1) ZA201507774B (sl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6975132B2 (ja) * 2015-07-20 2021-12-01 ゾエティス・サービシーズ・エルエルシー リポソームアジュバント組成物
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
BE1023538B1 (fr) * 2016-04-22 2017-04-26 Sil'innov Scrl Silices mésoporeuses et leur procédé de synthèse
KR20210068602A (ko) * 2016-06-02 2021-06-09 조에티스 서비시즈 엘엘씨 감염성 기관지염에 대한 백신
TW202206098A (zh) * 2020-08-11 2022-02-16 美商碩騰服務公司 抗冠狀病毒疫苗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7904021A (nl) * 1979-05-22 1980-04-29 Gist Brocades Nv Gecombineerd vaccin en werkwijze voor het bereiden van dit gecombineerd vaccin tegen door adeno achtige virussen veroorzaakte eiproduktiedalingen en door reo virus veroorzaakte ziekteverschijnselen.
US6803041B2 (en) * 2001-03-20 2004-10-12 Boehringer Ingelheim Vetmedica, Inc. Equine herpesvirus vaccine
WO2003061555A2 (en) * 2001-07-27 2003-07-31 Wyeth West nile vaccine
WO2004005476A2 (en) * 2002-07-03 2004-01-15 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
US20070166800A1 (en) * 2006-01-13 2007-07-19 Haixiang Lin Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
CN101517082B (zh) * 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
MX2009003325A (es) * 2006-10-12 2009-04-09 Glaxosmithkline Biolog Sa Vacuna que comprende un adyuvante de emulsion de aceite en agua.
DK2575878T3 (en) * 2010-05-28 2018-08-13 Zoetis Belgium S A VACCINES INCLUDING CHOLESTEROL AND CPG AS THE ONLY ADJUVENT CARRIER MOLECULES
ES2859673T3 (es) * 2010-11-08 2021-10-04 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis

Also Published As

Publication number Publication date
RU2627447C2 (ru) 2017-08-08
JP2016518446A (ja) 2016-06-23
PT3542819T (pt) 2021-10-14
CN105263518A (zh) 2016-01-20
EP2996719A1 (en) 2016-03-23
HUE056040T2 (hu) 2022-01-28
MX2019009407A (es) 2019-09-26
CA2911938A1 (en) 2014-11-20
LT3542819T (lt) 2021-11-10
AR096277A1 (es) 2015-12-16
DK3542819T3 (da) 2021-09-20
AU2014265649B2 (en) 2017-10-19
BR112015028748A2 (pt) 2017-09-19
ES2742325T3 (es) 2020-02-13
NZ713360A (en) 2021-06-25
ZA201507774B (en) 2017-09-27
PL3542819T3 (pl) 2022-01-10
SMT202100602T1 (it) 2021-11-12
JP6505084B2 (ja) 2019-04-24
MX367268B (es) 2019-08-12
HK1219426A1 (zh) 2017-04-07
JP2019108328A (ja) 2019-07-04
CA2911938C (en) 2019-07-16
EP3542819B1 (en) 2021-08-18
CA3027289A1 (en) 2014-11-20
AU2014265649A1 (en) 2015-11-12
CN108079290A (zh) 2018-05-29
RU2015146752A (ru) 2017-06-20
MX2015015758A (es) 2016-03-16
EP2996719B1 (en) 2019-06-26
PT2996719T (pt) 2019-09-03
AU2017232231A1 (en) 2017-10-12
CN105263518B (zh) 2018-03-20
WO2014186291A1 (en) 2014-11-20
ES2894138T3 (es) 2022-02-11
EP3542819A1 (en) 2019-09-25
HRP20211452T1 (hr) 2021-12-24

Similar Documents

Publication Publication Date Title
IL276210A (en) MERS-COV vaccine
IL279395A (en) A vaccine
ZA201801035B (en) Vaccine compositions
HK1212906A1 (zh) 疫苗組合物
PL2647387T3 (pl) Kompozycja szczepionki
EP2825196A4 (en) ADJUVANT AND VACCINE COMPOSITIONS
PT3091991T (pt) Composições imunomodulatórias
IL248223A0 (en) Compositions of vaccine
HK1224228A1 (zh) 新型製劑
IL243778A0 (en) Combined immune complexes
HK1218877A1 (zh) 粘膜疫苗組合物
HK1219426A1 (zh) 包含免疫刺激性寡核苷酸的新穎疫苗組合物
HK1217206A1 (zh) 疫苗
GB201316463D0 (en) Novel compositions
HK1219054A1 (zh) 粘膜疫苗組合物
PL3013363T3 (pl) Szczepionka przeciwko dyzenterii świń
IL243873A0 (en) Formulation of a saccharide component
GB201313990D0 (en) Combination immunogenic compositions
GB201320646D0 (en) Vaccine
GB201315556D0 (en) Vaccine
GB201322381D0 (en) Novel oligonucleotides
GB201304759D0 (en) Novel oligonucleotides
GB201315598D0 (en) Novel compositions